Get started
EyePoint Pharmaceuticals, Inc.EyePoint Pharmaceuticals, Inc.EyePoint Pharmaceuticals, Inc.

EyePoint Pharmaceuticals, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals Options

EYPT chart


Full chart

EYPT upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪447.08 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−2.31 USD
Net income (FY)
‪−130.87 M‬ USD
Revenue (FY)
‪43.27 M‬ USD
Shares float
‪59.62 M‬
Beta (1Y)
1.27

Employees


Employees (FY)
165
Change (1Y)
+44 +36.36%
Revenue / Employee (1Y)
‪262.26 K‬ USD
Net income / Employee (1Y)
‪−793.15 K‬ USD

About EyePoint Pharmaceuticals, Inc.


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Jay S. Duker
Website
eyepointpharma.com
Headquarters
Watertown
Founded
1987
FIGI
BBG000F90JX5
EyePoint Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that treat eye disorders. It offers FDA-approved sustained-release treatments in ophthalmology under the DEXYCU, ILUVIEN, Verisome, Retisert, and Durasert brands. The company was founded in 1987 and is headquartered in Watertown, MA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

EYPT news



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Check out other big names from the same industry as EYPT.

Frequently Asked Questions


The current price of EYPT is 6.71 USD — it has increased by 3.15% in the past 24 hours. Watch EyePoint Pharmaceuticals, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange EyePoint Pharmaceuticals, Inc. stocks are traded under the ticker EYPT.
EYPT stock has risen by 18.75% compared to the previous week, the month change is a 5.50% rise, over the last year EyePoint Pharmaceuticals, Inc. has showed a −63.25% decrease.
We've gathered analysts' opinions on EyePoint Pharmaceuticals, Inc. future price: according to them, EYPT price has a max estimate of 68.00 USD and a min estimate of 18.00 USD. Watch EYPT chart and read a more detailed EyePoint Pharmaceuticals, Inc. stock forecast: see what analysts think of EyePoint Pharmaceuticals, Inc. and suggest that you do with its stocks.
EYPT reached its all-time high on Jan 27, 2005 with the price of 485.60 USD, and its all-time low was 2.19 USD and was reached on Dec 16, 2022. View more price dynamics on EYPT chart.
See other stocks reaching their highest and lowest prices.
EYPT stock is 7.56% volatile and has beta coefficient of 1.27. Track EyePoint Pharmaceuticals, Inc. stock price on the chart and check out the list of the most volatile stocks — is EyePoint Pharmaceuticals, Inc. there?
Today EyePoint Pharmaceuticals, Inc. has the market capitalization of ‪447.08 M‬, it has increased by 5.48% over the last week.
Yes, you can track EyePoint Pharmaceuticals, Inc. financials in yearly and quarterly reports right on TradingView.
EyePoint Pharmaceuticals, Inc. is going to release the next earnings report on Apr 30, 2025. Keep track of upcoming events with our Earnings Calendar.
EYPT earnings for the last quarter are −0.64 USD per share, whereas the estimation was −0.49 USD resulting in a −31.66% surprise. The estimated earnings for the next quarter are −0.67 USD per share. See more details about EyePoint Pharmaceuticals, Inc. earnings.
EyePoint Pharmaceuticals, Inc. revenue for the last quarter amounts to ‪11.60 M‬ USD, despite the estimated figure of ‪11.08 M‬ USD. In the next quarter, revenue is expected to reach ‪7.89 M‬ USD.
EYPT net income for the last quarter is ‪−41.40 M‬ USD, while the quarter before that showed ‪−29.36 M‬ USD of net income which accounts for −41.00% change. Track more EyePoint Pharmaceuticals, Inc. financial stats to get the full picture.
No, EYPT doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Apr 23, 2025, the company has 165 employees. See our rating of the largest employees — is EyePoint Pharmaceuticals, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. EyePoint Pharmaceuticals, Inc. EBITDA is ‪−144.31 M‬ USD, and current EBITDA margin is −333.50%. See more stats in EyePoint Pharmaceuticals, Inc. financial statements.
Like other stocks, EYPT shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade EyePoint Pharmaceuticals, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So EyePoint Pharmaceuticals, Inc. technincal analysis shows the buy rating today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating EyePoint Pharmaceuticals, Inc. stock shows the sell signal. See more of EyePoint Pharmaceuticals, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.